Pure Global AI
NCT06392854Not yet recruiting

Regional Lipolysis Insulin Regulation

Insulin Regulation of Regional Lipolysis
Mayo ClinicPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
Insulin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Rochester, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Jul 01, 2028
Enrollment
48 participants
Primary outcome

palmitate release

Summary

Adults who gain most of their excess weight in the abdominal area typically do not respond to
 insulin in the same way as lean adults. Researchers are trying to understand why fat tissue
 responds differently in people with different body types.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06392854
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06392854 through Pure Global AI's free database. This Phase 1 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.